drugset / Trial / NCT02293603
Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
Phase 1
Unknown
42 enrolled
Capricor Inc.
Cedars-Sinai Medical Center · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collab
RandomizedSingle-groupQuadruple-blindTreatment
Summary
To determine the safety profile of CAP-1002 administered by multi-vessel intracoronary infusion in subjects with DCM. The study will further explore safety and exploratory efficacy endpoints of CAP-1002.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-05
- Completion
- 2020-04
Outcome
Met primary endpoint
release “CAP-1002 was well-tolerated in DYNAMIC. There were no events recorded for the primary safety endpoint, which was a composite of five cardiac event types.” capricor.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic Cardiosphere-Derived Cells (CDCs) | Cell therapy | — | Other |